Synjardy (empagliflozin and metformin)

Medically Reviewed on 6/30/2021

Generic drug: empagliflozin and metformin

Brand name: Synjardy

What is Synjardy (empagliflozin and metformin), and how does it work?

Synjardy (empagliflozin and metformin) is a prescription medicine used to treat the symptoms of Type 2 Diabetes Mellitus. Synjardy may be used alone or with other medications.

Synjardy belongs to a class of drugs called Antidiabetics, Biguanides; Antidiabetics, SGLT2 Inhibitors.

It is not known if Synjardy is safe and effective in children younger than 18 years of age.

What are the side effects of Synjardy?



Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (>5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL.

Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, and hepatic impairment.

Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided in the full prescribing information.

If metformin-associated lactic acidosis is suspected, immediately discontinue Synjardy and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended.

Synjardy may cause serious side effects including:

Get medical help right away, if you have any of the symptoms listed above.

The most common side effects of Synjardy include:

Tell the doctor if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of Synjardy. For more information, ask your doctor or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is the dosage for Synjardy?

Prior To Initiation Of Synjardy

  • Assess renal function before initiating Synjardy and as clinically indicated.
  • In patients with volume depletion, correct this condition before initiating Synjardy.

Recommended Dosage And Administration

  • Individualize the starting dose of Synjardy based on the patient’s current regimen:
    • In patients on metformin HCl, switch to Synjardy containing empagliflozin 5 mg with a similar total daily dose of metformin HCl;
    • In patients on empagliflozin, switch to Synjardy containing metformin HCl 500 mg with a similar total daily dose of empagliflozin;
    • In patients already treated with empagliflozin and metformin HCl, switch to Synjardy containing the same total daily doses of each component.
  • Monitor effectiveness and tolerability, and adjust dosing as appropriate, not to exceed the maximum recommended daily dose of empagliflozin 25 mg and metformin HCl 2000 mg.
  • Take Synjardy twice daily with meals; with gradual dose escalation to reduce the gastrointestinal side effects due to metformin.

Dosage Recommendations In Patients With Renal Impairment

  • Initiation of Synjardy is not recommended in patients with an eGFR less than 45 mL/min/1.73 m2, due to the metformin component.
  • Synjardy is contraindicated in patients with an eGFR less than 30 mL/min/1.73 m2 or in patients on dialysis.

Discontinuation For Iodinated Contrast Imaging Procedures

Discontinue Synjardy at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR less than 60 mL/min/1.73 m2; in patients with a history of liver disease, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast. Re-evaluate eGFR 48 hours after the imaging procedure; restart Synjardy if renal function is stable.


Type 2 Diabetes: Signs, Symptoms, Treatments See Slideshow

What drugs interact with Synjardy?

Table 4 Clinically Relevant Interactions with Synjardy

Carbonic Anhydrase Inhibitors
Clinical Impact Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) frequently causes a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis.
Intervention Concomitant use of these drugs with Synjardy may increase the risk of lactic acidosis. Consider more frequent monitoring of these patients.
Drugs that Reduce Metformin Clearance
Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis.
Intervention Consider the benefits and risks of concomitant use.
Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism.
Intervention Warn patients against excessive alcohol intake while receiving Synjardy.
Clinical Impact Coadministration of empagliflozin with diuretics resulted in increased urine volume and frequency of voids, which might enhance the potential for volume depletion.
Intervention Before initiating Synjardy, assess volume status and renal function. In patients with volume depletion, correct this condition before initiating Synjardy. Monitor for signs and symptoms of volume depletion, and renal function after initiating therapy.
Insulin or Insulin Secretagogues
Clinical Impact The risk of hypoglycemia is increased when empagliflozin is used in combination with insulin secretagogues (e.g., sulfonylurea) or insulin. Metformin may increase the risk of hypoglycemia when combined with insulin and/or an insulin secretagogue.
Intervention Coadministration of Synjardy with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower doses of the insulin secretagogue or insulin to reduce the risk of hypoglycemia.
Drugs Affecting Glycemic Control
Clinical Impact Certain drugs tend to produce hyperglycemia and may lead to loss of glycemic control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.
Intervention When such drugs are administered to a patient receiving Synjardy, the patient should be closely observed to maintain adequate glycemic control. When such drugs are withdrawn from a patient receiving Synjardy, the patient should be observed closely for hypoglycemia.
Positive Urine Glucose Test
Clinical Impact SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests.
Intervention Monitoring glycemic control with urine glucose tests is not recommended in patients taking SGLT2 inhibitors. Use alternative methods to monitor glycemic control.
Interference with 1,5-anhydroglucitol (1,5-AG) Assay
Clinical Impact Measurements of 1,5-AG are unreliable in assessing glycemic control in patients taking SGLT2 inhibitors.
Intervention Monitoring glycemic control with 1,5-AG assay is not recommended. Use alternative methods to monitor glycemic control.

Is Synjardy safe to use while pregnant or breastfeeding?

  • Advise pregnant patients, and patients of reproductive potential, of the potential risk to a fetus with treatment with Synjardy.
  • Instruct patients to report pregnancies to their physicians as soon as possible. Advise patients that breastfeeding is not recommended during treatment with Synjardy.


Synjardy (empagliflozin and metformin) is a prescription medicine used to treat the symptoms of Type 2 Diabetes Mellitus. Serious side effects of Synjardy include lactic acidosis, hives, difficulty breathing, swelling of your face, lips, tongue, or throat; burning or painful urination, frequent or urgent urination, pink or bloody urine, little or no urination, unusual vaginal or penis discharge, and others.

Treatment & Diagnosis

Medications & Supplements

Health Solutions From Our Sponsors

FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Medically Reviewed on 6/30/2021
All sections courtesy of the U.S. Food and Drug Administration